0001628280-26-059602.txt : 20260831 0001628280-26-059602.hdr.sgml : 20260831 20260831162525 ACCESSION NUMBER: 0001628280-26-059602 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20260831 ITEM INFORMATION: 1.05 FILED AS OF DATE: 20260831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services EIN: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 261346870 BUSINESS ADDRESS: STREET 1: 1776 YORKTOWN ST STREET 2: SUITE 700 CITY: HOUSTON STATE: TX ZIP: 77056 BUSINESS PHONE: (713) 660-0557 MAIL ADDRESS: STREET 1: 1776 YORKTOWN ST STREET 2: SUITE 700 CITY: HOUSTON STATE: TX ZIP: 77056 FORMER COMPANY: FORMER CONFORMED NAME: Nutex Health, Inc. DATE OF NAME CHANGE: 20220404 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx-20260831.htm 8-K nutx-20260831
0001479681FALSE00014796812026-08-312026-08-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
  
Date of Report (Date of earliest event reported): August 31, 2026
  
NUTEX HEALTH INC.
(Exact name of registrant as specified in its charter)
  
Delaware 
001-41346
11-3363609 
(State or Other Jurisdiction 
of Incorporation) 
(Commission File Number) 
(I.R.S. Employer 
Identification No.) 
  
1776 Yorktown Street, Suite 700, Houston, Texas 77056
(Address of principal executive offices) (zip code)
  
(713) 660-0557
(Registrant’s telephone number, including area code) 
  
N/A 
(Former name or former address, if changed since last report) 
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
  
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
  
Securities registered pursuant to Section 12(b) of the Act: 
  
Title of each class 
  
Trading Symbol(s) 
  
Name of each exchange on which registered 
Common Stock, $0.001 par value 
  
NUTX 
  
The NASDAQ Stock Market LLC 
  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 1.05 Material Cybersecurity Incidents.
As disclosed in Item 8.01 of a Current Report on Form 8-K filed with the Securities and Exchange Commission on August 24, 2026 (the “Prior 8-K”), Nutex Health Inc. (the “Company”) became aware of unauthorized activity involving data stored on its computer network. As disclosed in the Prior 8-K, the Company engaged an independent third-party cybersecurity response team and forensic experts, activated a cybersecurity response plan, implemented containment measures and notified law enforcement.
Based on the current status of the Company’s ongoing investigation, the Company believes that certain information maintained on the Company’s servers was accessed and exfiltrated by an unauthorized third party, including patient and employee, credentialed provider, business and financial information that is private and/or confidential. The third party has threatened to post such information externally. To date, the Company has not identified any material impact on its business operations or financial reporting systems.
The Company continues to assess whether, and to what extent, patient, employee, credentialed provider, confidential business and financial information, intellectual property, or other information may have been accessed, acquired, or exfiltrated and continues to evaluate the potential impact of the unauthorized activity on the Company, including any potential disclosure of private and/or confidential information by the third party. The Company continues to evaluate applicable regulatory and legal notification requirements, and the Company intends to make all required notifications based on its findings, including to impacted patients.
Following the filing of the Prior 8-K, a purported class action complaint captioned Haley v. Nutex Health, Inc., Case No. 4:26-cv-07197, was filed on August 27, 2026, against the Company in the United States District Court for the Southern District of Texas, Houston Division. The complaint was filed on behalf of a putative class of all individuals whose personally identifiable information and/or protected health information was allegedly accessed and/or acquired by an unauthorized party in connection with the incident. The complaint asserts claims for negligence, negligence per se, breach of third-party beneficiary contract, and unjust enrichment, and seeks, among other things, compensatory and consequential damages, injunctive relief, credit monitoring and identity theft insurance, and attorneys’ fees and costs.
At this stage, the Company is unable to predict the outcome of the litigation or estimate the potential impact of the incident on the Company’s business strategy, operations, financial condition, results of operations or the trading price of the Company’s common stock.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are included in this statement for purposes of complying with these safe harbor provisions. This document contains certain forward-looking statements with respect to current beliefs, understanding and expectations regarding the incident and its remediation and investigation. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as “estimate,” “project,” “predict,” “will,” “would,” “should,” “could,” “may,” “might,” “anticipate,” “plan,” “intend,” “believe,” “expect,” “aim,” “goal,” “target,” “objective,” “commit,” “advance,” “likely” or similar expressions that convey the prospective nature of events or outcomes.
These forward-looking statements reflect current beliefs, understanding and expectations regarding the incident and its remediation and investigation. Factors that could cause actual results to differ materially from those indicated in the forward-looking statements include, but are not limited to: litigation to which the Company has or may become subject in connection with the incident; the results of the Company’s ongoing investigation and analysis of the scope and details of the cybersecurity incident and the potential discovery of new and additional information related thereto; the Company’s expectations regarding its ability to contain and remediate the cybersecurity incident, including the success of containment and remediation activities to date; any unauthorized release of the Company’s data, including third-party data held by the Company, or the use of any such data for fraudulent purposes; potential loss or destruction of Company data or adverse impacts to the Company’s operations; the impact of the cybersecurity incident on the Company’s relationships with customers, employees, governmental regulators, and other stakeholders; diversion of management’s attention from the Company’s operations to addressing the cybersecurity incident; the legal, reputational, and financial risks resulting from the cybersecurity incident, including those that may arise from any potential regulatory inquiries; other reputational risk related to the cybersecurity incident; regulatory scrutiny of the cybersecurity incident; risks related to the availability of the Company’s insurance coverage for losses and costs associated with the cybersecurity incident; and remediation and other additional costs that may be incurred by the Company in connection with the investigation and




remediation of the incident. Readers are cautioned that these forward-looking statements are not guarantees of future events or outcomes and they should not be unduly relied on, as they are based on information available to the Company and on management’s current beliefs and expectations as of the date of this Current Report on Form 8-K and are therefore inherently uncertain and subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified in our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Annual Report on Form 10-K and our Quarterly reports on Form 10-Q for the periods ended March 31, 2026 and June 30, 2026. We undertake no obligation to revise or update any forward-looking statements, including to reflect events or circumstances occurring after the date of the filing of this report, except to the extent required by law.




 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
Date: August 31, 2026
NUTEX HEALTH INC. 
  
  
  
By: 
/s/ Jon C. Bates 
  
  
Jon C. Bates 
Chief Financial Officer 
  
  
 


EX-101.SCH 2 nutx-20260831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 nutx-20260831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Soliciting Material Soliciting Material Written Communications Written Communications Local Phone Number Local Phone Number Cover [Abstract] Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Central Index Key Entity Central Index Key Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Document Type Document Type City Area Code City Area Code EX-101.PRE 4 nutx-20260831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover
Aug. 31, 2026
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 31, 2026
Registrant Name NUTEX HEALTH INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41346
Entity Tax Identification Number 11-3363609
Entity Address, Address Line One 1776 Yorktown Street
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77056
City Area Code 713
Local Phone Number 660-0557
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol NUTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Central Index Key 0001479681
Amendment Flag false
XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://nutexhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nutx-20260831.htm nutx-20260831.xsd nutx-20260831_lab.xml nutx-20260831_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nutx-20260831.htm": { "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20260831", "dts": { "inline": { "local": [ "nutx-20260831.htm" ] }, "schema": { "local": [ "nutx-20260831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "labelLink": { "local": [ "nutx-20260831_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20260831_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://nutexhealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20260831.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20260831.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://nutexhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001628280-26-059602-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-26-059602-xbrl.zip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end XML 15 nutx-20260831_htm.xml IDEA: XBRL DOCUMENT 0001479681 2026-08-31 2026-08-31 0001479681 false 8-K 2026-08-31 NUTEX HEALTH INC. DE 001-41346 11-3363609 1776 Yorktown Street Suite 700 Houston TX 77056 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false